Wendy MBA - Reneo Pharmaceuticals Consultant
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Insider
Wendy MBA is Consultant of Reneo Pharmaceuticals
| Age | 72 |
| Phone | 858 283 0280 |
| Web | https://reneopharma.com |
Reneo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3372) % which means that it has lost $0.3372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.54) %, meaning that it created substantial loss on money invested by shareholders. Reneo Pharmaceuticals' management efficiency ratios could be used to measure how well Reneo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reneo Pharmaceuticals currently holds 973 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Reneo Pharmaceuticals has a current ratio of 15.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reneo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kelly Schick | C4 Therapeutics | 44 | |
| Timothy CPA | Werewolf Therapeutics | 66 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Ankur Dhingra | Summit Therapeutics PLC | 47 | |
| Elaine JD | Summit Therapeutics PLC | 63 | |
| Divya Chari | Summit Therapeutics PLC | 56 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Stephanie Yao | Kronos Bio | N/A | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| FRS DBE | Summit Therapeutics PLC | 73 | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| DSc MSE | Immix Biopharma | 75 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Mark Adams | Adaptive Biotechnologies Corp | 57 | |
| MBA MBA | Adaptive Biotechnologies Corp | 50 | |
| David Liu | Prime Medicine, Common | N/A | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 |
Reneo Pharmaceuticals Leadership Team
Elected by the shareholders, the Reneo Pharmaceuticals' board of directors comprises two types of representatives: Reneo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reneo. The board's role is to monitor Reneo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reneo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reneo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Flesher, CEO President | ||
| Alejandro MD, Chief Officer | ||
| Ashley JD, Chief Officer | ||
| Wendy MBA, Consultant | ||
| Vineet Jindal, Consultant | ||
| Michael Cruse, Chief Officer | ||
| Jennifer Lam, Principal Officer | ||
| Lynn Purkins, Senior Development | ||
| Michael Grey, Founder Chairman |
Reneo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reneo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |